Maxim’s healthcare analyst Jason Kolbert came out with a positive commentary on TrovaGene Inc (NASDAQ:TROV), following the news that the company’s urine-based HPV HR Test is equally capable of detecting …
In a research report published yesterday, Cantor analyst Bryan Brokmeier initiated coverage on shares of TrovaGene Inc (NASDAQ:TROV) with a Buy rating and price …
TrovaGene Inc (NASDAQ:TROV), a developer of cell-free molecular diagnostics, announced today the establishment of Trovagene Research Institute (TRI), a European subsidiary focused on expanding …
TrovaGene Inc (NASDAQ:TROV), a developer of cell-free molecular diagnostics, announced today that clinical data featuring its Precision Cancer Monitoring℠ platform will be presented at …
TrovaGene Inc (NASDAQ:TROV), a developer of cell-free molecular diagnostics, today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock. …
TrovaGene Inc (NASDAQ:TROV), a developer of cell-free molecular diagnostics, announced that it is offering to sell shares of its common stock in an …
Maxim Group analyst Jason Kolbert was out pounding the table on TrovaGene Inc (NASDAQ:TROV) Thursday, reiterating a Buy rating and price target of $13, …
In a research report issued today, Cantor analyst Sung Ji Nam reiterated a Buy rating on TrovaGene Inc (NASDAQ:TROV) with an $8 price target, after several …